Carbon-Ion Radiotherapy for Prostate Cancer in Patients with a History of Surgery for Benign Prostatic Hyperplasia
<b>Background/Objectives</b>: Carbon-ion radiotherapy (CIRT) offers precise dose distribution and enhanced biological effectiveness in localized prostate cancer. However, the safety of CIRT in patients with a history of surgery for benign prostatic hyperplasia (BPH), such as transurethral resection of the prostate (TURP), remains unclear. This study aimed to evaluate the long-term safety and oncological outcomes of CIRT in this population. <b>Methods:</b> A retrospective analysis was conducted in 74 of 3848 patients with prostate cancer and a history of surgery for BPH who underwent CIRT combined with risk-adapted androgen deprivation therapy between 2007 and 2023. Adverse events were assessed using CTCAE v5.0. Biochemical recurrence-free survival was estimated using the Kaplan-Meier method and risk factors for hematuria with multivariate logistic regression and receiver operation characteristic (ROC) analysis. <b>Results:</b> CIRT was generally well-tolerated. Early Grade 2 genitourinary (GU) adverse events occurred in 5.4% of patients, and late-Grade 2 or higher GU events occurred in 8.1%. The cumulative incidence of Grade 2 ≥ GU events remained 10% at 36 months. Compared to holmium laser enucleation of the prostate, a shorter interval between BPH surgery and CIRT initiation and a history of TURP were independently associated with an increased risk of hematuria. Notably, 5-year bRFS was 100% in low- and intermediate-risk groups and 88.6% in the high-risk group. <b>Conclusions:</b> CIRT demonstrates acceptable oncological outcomes and urinary complication rates in patients with prostate cancer and a history of BPH surgery. These findings suggest that CIRT can be a feasible treatment option in this surgically altered population, but careful patient selection, individualized treatment planning, and long-term follow-up are essential. Given the absence of a non-BPH control group, oncological efficacy should be interpreted with caution.
Authors
- Kosei Miura (ORCID: https://orcid.org/0000-0003-2763-9026)
- Atsushi Okato (ORCID: https://orcid.org/0000-0002-4207-9744)
- Koichiro Akakura (ORCID: https://orcid.org/0000-0003-4368-1574)
- Masaru Wakatsuki
- Tomohiko Ichikawa (ORCID: https://orcid.org/0000-0002-8637-4163)
- Hiroshi Tsuji
- Takanobu Utsumi (ORCID: https://orcid.org/0000-0002-9423-7361)
- Hitoshi Ishikawa (ORCID: https://orcid.org/0000-0002-0046-9787)
- Hirokazu Makishima (ORCID: https://orcid.org/0000-0003-0380-0778)
- Mio Nakajima (ORCID: https://orcid.org/0000-0002-1630-1639)
- Hiroyoshi Suzuki (ORCID: https://orcid.org/0000-0001-5838-114X)
- T. Yamaguchi
Institutions
- Toho University (JP)
- Institute of Particle Physics (CA)
- National Institutes for Quantum Science and Technology (JP)
- Toho University Medical Center Sakura Hospital (JP)
- Japan Community Healthcare Organization (JP)
Publication Details
- Journal
- Cancers
- Published
- 2025-09-17
- DOI
- https://doi.org/10.3390/cancers17183039
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00